Copyright Reports & Markets. All rights reserved.

Global Platinum-based Anticancer APIs Market Research Report 2021

Request for Sample of this report
Buy now

1 Platinum-based Anticancer APIs Market Overview

  • 1.1 Product Overview and Scope of Platinum-based Anticancer APIs
  • 1.2 Platinum-based Anticancer APIs Segment by Type
    • 1.2.1 Global Platinum-based Anticancer APIs Market Size Growth Rate Analysis by Type 2021 VS 2027
    • 1.2.2 Cisplatin
    • 1.2.3 Carboplatin
    • 1.2.4 Oxaliplatin
    • 1.2.5 Nedaplatin
    • 1.2.6 Others
  • 1.3 Platinum-based Anticancer APIs Segment by Application
    • 1.3.1 Global Platinum-based Anticancer APIs Consumption Comparison by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Testicular Cancer
    • 1.3.3 Osteosarcoma
    • 1.3.4 Breast Cancer
    • 1.3.5 Esophageal Cancer
    • 1.3.6 NSCLC
    • 1.3.7 Other
  • 1.4 Global Market Growth Prospects
    • 1.4.1 Global Platinum-based Anticancer APIs Revenue Estimates and Forecasts (2016-2027)
    • 1.4.2 Global Platinum-based Anticancer APIs Production Capacity Estimates and Forecasts (2016-2027)
    • 1.4.3 Global Platinum-based Anticancer APIs Production Estimates and Forecasts (2016-2027)
  • 1.5 Global Platinum-based Anticancer APIs Market by Region
    • 1.5.1 Global Platinum-based Anticancer APIs Market Size Estimates and Forecasts by Region: 2016 VS 2021 VS 2027
    • 1.5.2 North America Platinum-based Anticancer APIs Estimates and Forecasts (2016-2027)
    • 1.5.3 Europe Platinum-based Anticancer APIs Estimates and Forecasts (2016-2027)
    • 1.5.5 China Platinum-based Anticancer APIs Estimates and Forecasts (2016-2027)
    • 1.5.5 India Platinum-based Anticancer APIs Estimates and Forecasts (2016-2027)

2 Market Competition by Manufacturers

  • 2.1 Global Platinum-based Anticancer APIs Production Capacity Market Share by Manufacturers (2016-2021)
  • 2.2 Global Platinum-based Anticancer APIs Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Platinum-based Anticancer APIs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.4 Global Platinum-based Anticancer APIs Average Price by Manufacturers (2016-2021)
  • 2.5 Manufacturers Platinum-based Anticancer APIs Production Sites, Area Served, Product Types
  • 2.6 Platinum-based Anticancer APIs Market Competitive Situation and Trends
    • 2.6.1 Platinum-based Anticancer APIs Market Concentration Rate
    • 2.6.2 Global 5 and 10 Largest Platinum-based Anticancer APIs Players Market Share by Revenue
    • 2.6.3 Mergers & Acquisitions, Expansion

3 Production and Capacity by Region

  • 3.1 Global Production Capacity of Platinum-based Anticancer APIs Market Share by Region (2016-2021)
  • 3.2 Global Platinum-based Anticancer APIs Revenue Market Share by Region (2016-2021)
  • 3.3 Global Platinum-based Anticancer APIs Production, Revenue, Price and Gross Margin (2016-2021)
  • 3.4 North America Platinum-based Anticancer APIs Production
    • 3.4.1 North America Platinum-based Anticancer APIs Production Growth Rate (2016-2021)
    • 3.4.2 North America Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
  • 3.5 Europe Platinum-based Anticancer APIs Production
    • 3.5.1 Europe Platinum-based Anticancer APIs Production Growth Rate (2016-2021)
    • 3.5.2 Europe Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
  • 3.6 China Platinum-based Anticancer APIs Production
    • 3.6.1 China Platinum-based Anticancer APIs Production Growth Rate (2016-2021)
    • 3.6.2 China Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
  • 3.7 India Platinum-based Anticancer APIs Production
    • 3.7.1 India Platinum-based Anticancer APIs Production Growth Rate (2016-2021)
    • 3.7.2 India Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

4 Global Platinum-based Anticancer APIs Consumption by Region

  • 4.1 Global Platinum-based Anticancer APIs Consumption by Region
    • 4.1.1 Global Platinum-based Anticancer APIs Consumption by Region
    • 4.1.2 Global Platinum-based Anticancer APIs Consumption Market Share by Region
  • 4.2 North America
    • 4.2.1 North America Platinum-based Anticancer APIs Consumption by Country
    • 4.2.2 U.S.
    • 4.2.3 Canada
  • 4.3 Europe
    • 4.3.1 Europe Platinum-based Anticancer APIs Consumption by Country
    • 4.3.2 Germany
    • 4.3.3 France
    • 4.3.4 U.K.
    • 4.3.5 Italy
    • 4.3.6 Russia
  • 4.4 Asia Pacific
    • 4.4.1 Asia Pacific Platinum-based Anticancer APIs Consumption by Region
    • 4.4.2 China
    • 4.4.3 Japan
    • 4.4.4 South Korea
    • 4.4.5 Taiwan
    • 4.4.6 Southeast Asia
    • 4.4.7 India
    • 4.4.8 Australia
  • 4.5 Latin America
    • 4.5.1 Latin America Platinum-based Anticancer APIs Consumption by Country
    • 4.5.2 Mexico
    • 4.5.3 Brazil

5 Production, Revenue, Price Trend by Type

  • 5.1 Global Platinum-based Anticancer APIs Production Market Share by Type (2016-2021)
  • 5.2 Global Platinum-based Anticancer APIs Revenue Market Share by Type (2016-2021)
  • 5.3 Global Platinum-based Anticancer APIs Price by Type (2016-2021)

6 Consumption Analysis by Application

  • 6.1 Global Platinum-based Anticancer APIs Consumption Market Share by Application (2016-2021)
  • 6.2 Global Platinum-based Anticancer APIs Consumption Growth Rate by Application (2016-2021)

7 Key Companies Profiled

  • 7.1 Jiangsu Hengrui Medicine
    • 7.1.1 Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Corporation Information
    • 7.1.2 Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Product Portfolio
    • 7.1.3 Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.1.4 Jiangsu Hengrui Medicine Main Business and Markets Served
    • 7.1.5 Jiangsu Hengrui Medicine Recent Developments/Updates
  • 7.2 Nanjing Pharmaceutical Factory
    • 7.2.1 Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Corporation Information
    • 7.2.2 Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Product Portfolio
    • 7.2.3 Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.2.4 Nanjing Pharmaceutical Factory Main Business and Markets Served
    • 7.2.5 Nanjing Pharmaceutical Factory Recent Developments/Updates
  • 7.3 Qilu Pharmaceutical
    • 7.3.1 Qilu Pharmaceutical Platinum-based Anticancer APIs Corporation Information
    • 7.3.2 Qilu Pharmaceutical Platinum-based Anticancer APIs Product Portfolio
    • 7.3.3 Qilu Pharmaceutical Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.3.4 Qilu Pharmaceutical Main Business and Markets Served
    • 7.3.5 Qilu Pharmaceutical Recent Developments/Updates
  • 7.4 Neptunus
    • 7.4.1 Neptunus Platinum-based Anticancer APIs Corporation Information
    • 7.4.2 Neptunus Platinum-based Anticancer APIs Product Portfolio
    • 7.4.3 Neptunus Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.4.4 Neptunus Main Business and Markets Served
    • 7.4.5 Neptunus Recent Developments/Updates
  • 7.5 Hisun
    • 7.5.1 Hisun Platinum-based Anticancer APIs Corporation Information
    • 7.5.2 Hisun Platinum-based Anticancer APIs Product Portfolio
    • 7.5.3 Hisun Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.5.4 Hisun Main Business and Markets Served
    • 7.5.5 Hisun Recent Developments/Updates
  • 7.6 Jiangsu HaiCi biological pharmaceutical
    • 7.6.1 Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Corporation Information
    • 7.6.2 Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Product Portfolio
    • 7.6.3 Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.6.4 Jiangsu HaiCi biological pharmaceutical Main Business and Markets Served
    • 7.6.5 Jiangsu HaiCi biological pharmaceutical Recent Developments/Updates
  • 7.7 Kunming Guiyan Pharmaceutical
    • 7.7.1 Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Corporation Information
    • 7.7.2 Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Product Portfolio
    • 7.7.3 Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.7.4 Kunming Guiyan Pharmaceutical Main Business and Markets Served
    • 7.7.5 Kunming Guiyan Pharmaceutical Recent Developments/Updates
  • 7.8 Lingnan Pharmacy
    • 7.8.1 Lingnan Pharmacy Platinum-based Anticancer APIs Corporation Information
    • 7.8.2 Lingnan Pharmacy Platinum-based Anticancer APIs Product Portfolio
    • 7.8.3 Lingnan Pharmacy Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.8.4 Lingnan Pharmacy Main Business and Markets Served
    • 7.7.5 Lingnan Pharmacy Recent Developments/Updates
  • 7.9 Jinzhou Jiutai Pharmaceutical
    • 7.9.1 Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Corporation Information
    • 7.9.2 Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Product Portfolio
    • 7.9.3 Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.9.4 Jinzhou Jiutai Pharmaceutical Main Business and Markets Served
    • 7.9.5 Jinzhou Jiutai Pharmaceutical Recent Developments/Updates
  • 7.10 Nanjing Hairun Pharmaceutical
    • 7.10.1 Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Corporation Information
    • 7.10.2 Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Product Portfolio
    • 7.10.3 Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.10.4 Nanjing Hairun Pharmaceutical Main Business and Markets Served
    • 7.10.5 Nanjing Hairun Pharmaceutical Recent Developments/Updates
  • 7.11 Simcere
    • 7.11.1 Simcere Platinum-based Anticancer APIs Corporation Information
    • 7.11.2 Simcere Platinum-based Anticancer APIs Product Portfolio
    • 7.11.3 Simcere Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.11.4 Simcere Main Business and Markets Served
    • 7.11.5 Simcere Recent Developments/Updates
  • 7.12 Teva
    • 7.12.1 Teva Platinum-based Anticancer APIs Corporation Information
    • 7.12.2 Teva Platinum-based Anticancer APIs Product Portfolio
    • 7.12.3 Teva Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.12.4 Teva Main Business and Markets Served
    • 7.12.5 Teva Recent Developments/Updates
  • 7.13 Cipla
    • 7.13.1 Cipla Platinum-based Anticancer APIs Corporation Information
    • 7.13.2 Cipla Platinum-based Anticancer APIs Product Portfolio
    • 7.13.3 Cipla Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.13.4 Cipla Main Business and Markets Served
    • 7.13.5 Cipla Recent Developments/Updates
  • 7.14 Heraeus
    • 7.14.1 Heraeus Platinum-based Anticancer APIs Corporation Information
    • 7.14.2 Heraeus Platinum-based Anticancer APIs Product Portfolio
    • 7.14.3 Heraeus Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.14.4 Heraeus Main Business and Markets Served
    • 7.14.5 Heraeus Recent Developments/Updates
  • 7.15 Hospira(Pfizer)
    • 7.15.1 Hospira(Pfizer) Platinum-based Anticancer APIs Corporation Information
    • 7.15.2 Hospira(Pfizer) Platinum-based Anticancer APIs Product Portfolio
    • 7.15.3 Hospira(Pfizer) Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.15.4 Hospira(Pfizer) Main Business and Markets Served
    • 7.15.5 Hospira(Pfizer) Recent Developments/Updates
  • 7.16 Taj Pharmaceuticals
    • 7.16.1 Taj Pharmaceuticals Platinum-based Anticancer APIs Corporation Information
    • 7.16.2 Taj Pharmaceuticals Platinum-based Anticancer APIs Product Portfolio
    • 7.16.3 Taj Pharmaceuticals Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.16.4 Taj Pharmaceuticals Main Business and Markets Served
    • 7.16.5 Taj Pharmaceuticals Recent Developments/Updates
  • 7.17 Umicore Precious Metals Chemistry
    • 7.17.1 Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Corporation Information
    • 7.17.2 Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Product Portfolio
    • 7.17.3 Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
    • 7.17.4 Umicore Precious Metals Chemistry Main Business and Markets Served
    • 7.17.5 Umicore Precious Metals Chemistry Recent Developments/Updates

8 Platinum-based Anticancer APIs Manufacturing Cost Analysis

  • 8.1 Platinum-based Anticancer APIs Key Raw Materials Analysis
    • 8.1.1 Key Raw Materials
    • 8.1.2 Key Raw Materials Price Trend
    • 8.1.3 Key Suppliers of Raw Materials
  • 8.2 Proportion of Manufacturing Cost Structure
  • 8.3 Manufacturing Process Analysis of Platinum-based Anticancer APIs
  • 8.4 Platinum-based Anticancer APIs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

  • 9.1 Marketing Channel
  • 9.2 Platinum-based Anticancer APIs Distributors List
  • 9.3 Platinum-based Anticancer APIs Customers

10 Market Dynamics

  • 10.1 Platinum-based Anticancer APIs Industry Trends
  • 10.2 Platinum-based Anticancer APIs Growth Drivers
  • 10.3 Platinum-based Anticancer APIs Market Challenges
  • 10.4 Platinum-based Anticancer APIs Market Restraints

11 Production and Supply Forecast

  • 11.1 Global Forecasted Production of Platinum-based Anticancer APIs by Region (2022-2027)
  • 11.2 North America Platinum-based Anticancer APIs Production, Revenue Forecast (2022-2027)
  • 11.3 Europe Platinum-based Anticancer APIs Production, Revenue Forecast (2022-2027)
  • 11.4 China Platinum-based Anticancer APIs Production, Revenue Forecast (2022-2027)
  • 11.5 India Platinum-based Anticancer APIs Production, Revenue Forecast (2022-2027)

12 Consumption and Demand Forecast

  • 12.1 Global Forecasted Demand Analysis of Platinum-based Anticancer APIs
  • 12.2 North America Forecasted Consumption of Platinum-based Anticancer APIs by Country
  • 12.3 Europe Market Forecasted Consumption of Platinum-based Anticancer APIs by Country
  • 12.4 Asia Pacific Market Forecasted Consumption of Platinum-based Anticancer APIs by Region
  • 12.5 Latin America Forecasted Consumption of Platinum-based Anticancer APIs by Country

13 Forecast by Type and by Application (2022-2027)

  • 13.1 Global Production, Revenue and Price Forecast by Type (2022-2027)
    • 13.1.1 Global Forecasted Production of Platinum-based Anticancer APIs by Type (2022-2027)
    • 13.1.2 Global Forecasted Revenue of Platinum-based Anticancer APIs by Type (2022-2027)
    • 13.1.3 Global Forecasted Price of Platinum-based Anticancer APIs by Type (2022-2027)
  • 13.2 Global Forecasted Consumption of Platinum-based Anticancer APIs by Application (2022-2027)

14 Research Finding and Conclusion

    15 Methodology and Data Source

    • 15.1 Methodology/Research Approach
      • 15.1.1 Research Programs/Design
      • 15.1.2 Market Size Estimation
      • 15.1.3 Market Breakdown and Data Triangulation
    • 15.2 Data Source
      • 15.2.1 Secondary Sources
      • 15.2.2 Primary Sources
    • 15.3 Author List

    The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027. by Application segment also provides consumption during the forecast period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Cisplatin
    Carboplatin
    Oxaliplatin
    Nedaplatin
    Others

    Segment by Application
    Testicular Cancer
    Osteosarcoma
    Breast Cancer
    Esophageal Cancer
    NSCLC
    Other

    By Company
    Jiangsu Hengrui Medicine
    Nanjing Pharmaceutical Factory
    Qilu Pharmaceutical
    Neptunus
    Hisun
    Jiangsu HaiCi biological pharmaceutical
    Kunming Guiyan Pharmaceutical
    Lingnan Pharmacy
    Jinzhou Jiutai Pharmaceutical
    Nanjing Hairun Pharmaceutical
    Simcere
    Teva
    Cipla
    Heraeus
    Hospira(Pfizer)
    Taj Pharmaceuticals
    Umicore Precious Metals Chemistry

    Production by Region
    North America
    Europe
    China
    India

    Consumption by Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    Buy now